A Combination of Savolitinib and Osimertinib Prolongs PFS in Patients with EGFR-mutated NSCLC and Acquired MET Amplification After Progression On a First-Line EGFR TKI By Ogkologos - January 16, 2026 281 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the SACHI study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Generic Palbociclib Metastasis-Directed Therapy for Oligometastatic Solid Tumours in Histology-Specific Context ctDNA Testing After Neoadjuvant Chemotherapy and Radical Cystectomy Predicts Recurrence Risk in Patients with MIBC MOST POPULAR Reunión anual de la American Society of Clinical Oncology de 2023:... May 25, 2023 Pembrolizumab May Help Prevent Early-Stage Melanoma from Returning October 13, 2021 Osimertinib Shows Promising Activity in Previously Untreated Patients with Metastatic NSCLC... December 19, 2023 EMA Recommends Granting a Marketing Authorisation for Sacituzumab Govitecan October 25, 2021 Load more HOT NEWS Welcome to our new committee chairs Cleveland Clinic Launches Breast Cancer Vaccine Trial From athlete to wig-maker: how cancer changed Maria’s destiny Mom Fighting Breast Cancer Says Her Haunted House Is Something To...
